HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neuroprotective effects of minocycline and KML29, a potent inhibitor of monoacylglycerol lipase, in an experimental stroke model: a small-animal positron emission tomography study.

Abstract
Hypoxia caused by ischemia induces acidosis and neuroexcitotoxicity, resulting in neuronal death in the central nervous system (CNS). Monoacylglycerol lipase (MAGL) is a modulator of 2-arachidonoylglycerol (2-AG), which is involved in retrograde inhibition of glutamate release in the endocannabinoid system. In the present study, we used positron emission tomography (PET) to monitor MAGL-positive neurons and neuroinflammation in the brains of ischemic rats. Additionally, we performed PET imaging to evaluate the neuroprotective effects of an MAGL inhibitor in an ischemic injury model. Methods: Ischemic-injury rat models were induced by intraluminal right middle cerebral artery occlusion (MCAO). PET studies of the brains of the ischemic rats were performed at several experimental time points (pre-occlusion, days 2, 4, and 7 after the MCAO surgery) using [11C]SAR127303 for MAGL and [18F]FEBMP for 18 kDa translocator protein (TSPO, a hall-mark of neuroinflammation). Medication using minocycline (a well-known neuroprotective agent) or KML29 (a potent MAGL inhibitor) was given immediately after the MCAO surgery and then daily over the subsequent three days. Results: PET imaging of the ischemic rats using [11C]SAR127303 showed an acute decline of radioactive accumulation in the ipsilateral side at two days after MCAO surgery (ratio of the area under the curve between the ipsilateral and contralateral sides: 0.49 ± 0.04 in the cortex and 0.73 ± 0.02 in the striatum). PET imaging with [18F]FEBMP, however, showed a moderate increase in accumulation of radioactivity in the ipsilateral hemisphere on day 2 (1.36 ± 0.11), and further increases on day 4 (1.72 ± 0.15) and day 7 (1.99 ± 0.06). Treatment with minocycline or KML29 eased the decline in radioactive accumulation of [11C]SAR127303 for MAGL (minocycline-treated group: 0.82 ± 0.06 in the cortex and 0.81 ± 0.05 in the striatum; KML29-treated group: 0.72 ± 0.07 in the cortex and 0.88 ± 0.04 in the striatum) and increased uptake of [18F]FEBMP for TSPO (minocycline-treated group: 1.52 ± 0.21 in the cortex and 1.56 ± 0.11 in the striatum; KML29-treated group: 1.63 ± 0.09 in the cortex and 1.50 ± 0.17 in the striatum). In MCAO rats, minocycline treatment showed a neuroprotective effect in the sensorimotor cortex suffering from severe hypoxic injury, whereas KML29 treatment saved neurons in the striatum, including bundles of myelinated axons. Conclusions: PET imaging allowed visualization of the different neuroprotective effects of minocycline and KML29, and indicated that combination pharmacotherapy using these drugs may be an effective therapy in acute ischemia.
AuthorsTomoteru Yamasaki, Akiko Hatori, Yiding Zhang, Wakana Mori, Yusuke Kurihara, Masanao Ogawa, Hidekatsu Wakizaka, Jian Rong, Lu Wang, Steven Liang, Ming-Rong Zhang
JournalTheranostics (Theranostics) Vol. 11 Issue 19 Pg. 9492-9502 ( 2021) ISSN: 1838-7640 [Electronic] Australia
PMID34646382 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The author(s).
Chemical References
  • 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(benzo(d)(1,3)dioxol-5-yl)(hydroxy)methyl)piperidine-1-carboxylate
  • Arachidonic Acids
  • Benzodioxoles
  • Carbon Radioisotopes
  • Endocannabinoids
  • Glycerides
  • Neuroprotective Agents
  • Piperidines
  • glyceryl 2-arachidonate
  • Monoacylglycerol Lipases
  • Minocycline
Topics
  • Animals
  • Arachidonic Acids (metabolism)
  • Benzodioxoles (metabolism, pharmacology)
  • Brain (metabolism)
  • Brain Ischemia (metabolism)
  • Carbon Radioisotopes (metabolism)
  • Cell Hypoxia (physiology)
  • Disease Models, Animal
  • Endocannabinoids (metabolism)
  • Glycerides (metabolism)
  • Infarction, Middle Cerebral Artery (metabolism)
  • Ischemic Stroke (drug therapy)
  • Male
  • Minocycline (metabolism, pharmacology)
  • Monoacylglycerol Lipases (antagonists & inhibitors, metabolism)
  • Neuroprotective Agents (pharmacology)
  • Piperidines (metabolism, pharmacology)
  • Positron-Emission Tomography (veterinary)
  • Rats
  • Rats, Sprague-Dawley
  • Stroke (drug therapy)
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: